On July 21, 2020, Nature’s “Scientific Reports” published the research result “Selection of mutant µplasmin for amyloid-β cleavage in vivo” by Dr. Yang Dongying from the School of Medicine and Nursing of our school as the first author.
This technology is one of the core technologies of protein drug research and development, which opens up a feasible way for the development of special protein drugs. Based on the research and development of this technology, our school has actively carried out scientific and technological services in fungal research, animal experimental research on the sequel of pulmonary fibrosis after the new coronavirus, and received support from relevant drug research and development companies, and so far, received research funding of 500,000 yuan.
